Background. Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of everolimus efficacy have been investigated in primary breast cancer tissue without finding univocal results. The goal of this study was to investigate the mutational burden in the metastatic site of endocrine-resistant tumors treated with everolimus plus exemestane. Patients and Methods. Mass Array Sequenom platform was used to analyse genetic status of 18 cancer-related genes in 25 archival tumor specimens from metastatic lesions and available primary matched breast cancer tissue of patients treated with everolimus and exemestane for advanced disease. An exploratory analysis of everolimus efficacy in terms of progression free survival benefit and single gene mutation was carried out. Results. The overall detection rate of mutation was 30% and 38% from metastatic and primary breast cancer samples, respectively. was the most frequent mutated gene. No primary breast cancer and matched relapse maintained the same mutation profile. Considering molecular pathways, the most of the genes belong to PI3K pathway (, , and ). In patients with detected mutations in breast and/or recurrence tissue the median PFS was 5,6 months while in the subgroup of patients with no mutations the median PFS was 7,5 months. Conclusions. The mutational status of breast cancer recurrence allows the identification of some genes potentially correlating tumor response/resistance to everolimus. The most frequently mutated genes were involved in the PI3K/AKT/mTOR pathway highlighting that the deregulation of this pathway in the relapse plays a crucial role in the mechanisms of everolimus resistance/sensitivity. Owing to the small sample size and the retrospective nature of the study, these correlations need to be validated in a large prospective study.

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus / Omarini, Claudia; Filieri, Maria Elisabetta; Bettelli, Stefania Raffaella; Manfredini, Samantha; Kaleci, Shaniko; Caprera, Cecilia; Nasso, Cecilia; Barbolini, Monica; Guaitoli, Giorgia; Moscetti, Luca; Maiorana, Antonino; Conte, Pierfranco; Cascinu, Stefano; Piacentini, Federico. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - 2018:(2018), pp. 1-8. [10.1155/2018/3756981 ]

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

Claudia Omarini;Maria Elisabetta Filieri;Stefania Bettelli;Samantha Manfredini;Shaniko Kaleci;Cecilia Nasso;Monica Barbolini;Giorgia Guaitoli;Antonino Maiorana;Pier Franco Conte;Stefano Cascinu;Federico Piacentini
2018

Abstract

Background. Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of everolimus efficacy have been investigated in primary breast cancer tissue without finding univocal results. The goal of this study was to investigate the mutational burden in the metastatic site of endocrine-resistant tumors treated with everolimus plus exemestane. Patients and Methods. Mass Array Sequenom platform was used to analyse genetic status of 18 cancer-related genes in 25 archival tumor specimens from metastatic lesions and available primary matched breast cancer tissue of patients treated with everolimus and exemestane for advanced disease. An exploratory analysis of everolimus efficacy in terms of progression free survival benefit and single gene mutation was carried out. Results. The overall detection rate of mutation was 30% and 38% from metastatic and primary breast cancer samples, respectively. was the most frequent mutated gene. No primary breast cancer and matched relapse maintained the same mutation profile. Considering molecular pathways, the most of the genes belong to PI3K pathway (, , and ). In patients with detected mutations in breast and/or recurrence tissue the median PFS was 5,6 months while in the subgroup of patients with no mutations the median PFS was 7,5 months. Conclusions. The mutational status of breast cancer recurrence allows the identification of some genes potentially correlating tumor response/resistance to everolimus. The most frequently mutated genes were involved in the PI3K/AKT/mTOR pathway highlighting that the deregulation of this pathway in the relapse plays a crucial role in the mechanisms of everolimus resistance/sensitivity. Owing to the small sample size and the retrospective nature of the study, these correlations need to be validated in a large prospective study.
25-lug-2018
2018
1
8
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus / Omarini, Claudia; Filieri, Maria Elisabetta; Bettelli, Stefania Raffaella; Manfredini, Samantha; Kaleci, Shaniko; Caprera, Cecilia; Nasso, Cecilia; Barbolini, Monica; Guaitoli, Giorgia; Moscetti, Luca; Maiorana, Antonino; Conte, Pierfranco; Cascinu, Stefano; Piacentini, Federico. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - 2018:(2018), pp. 1-8. [10.1155/2018/3756981 ]
Omarini, Claudia; Filieri, Maria Elisabetta; Bettelli, Stefania Raffaella; Manfredini, Samantha; Kaleci, Shaniko; Caprera, Cecilia; Nasso, Cecilia; Barbolini, Monica; Guaitoli, Giorgia; Moscetti, Luca; Maiorana, Antonino; Conte, Pierfranco; Cascinu, Stefano; Piacentini, Federico
File in questo prodotto:
File Dimensione Formato  
Mutational Profile of Metastatic Breast Cancer Tissue in.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.89 MB
Formato Adobe PDF
1.89 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1164642
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact